Wingate Wealth Advisors Inc. Invests $63,000 in Zoetis Inc. (NYSE:ZTS)

Wingate Wealth Advisors Inc. bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 4th quarter, Holdings Channel reports. The firm bought 386 shares of the company’s stock, valued at approximately $63,000.

Other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services acquired a new position in shares of Zoetis during the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the third quarter valued at $33,000. Dunhill Financial LLC lifted its stake in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Fortitude Family Office LLC lifted its stake in shares of Zoetis by 1,387.5% during the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler cut their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Morgan Stanley cut their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $214.00.

Zoetis Trading Up 0.2 %

NYSE ZTS opened at $171.71 on Tuesday. The firm has a market cap of $77.47 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock’s 50-day moving average is $169.26 and its 200-day moving average is $179.21. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.